يعرض 1 - 10 نتائج من 254 نتيجة بحث عن '"Second Primary"', وقت الاستعلام: 1.22s تنقيح النتائج
  1. 1
  2. 2
  3. 3

    المساهمون: Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)

    المصدر: BMC Cancer, Vol 19, Iss 1, Pp 1-17 (2019)
    BMC Cancer
    BMC Cancer, BioMed Central, 2019, 19 (1), ⟨10.1186/s12885-019-5507-6⟩

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, erlotinib, Afatinib, afatinib, clinical outcome, Pembrolizumab, [SPI.MAT]Engineering Sciences [physics]/Materials, chemistry.chemical_compound, 0302 clinical medicine, systematic review, Carcinoma, Non-Small-Cell Lung, Neoplasms, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, nintedanib, docetaxel, advanced cancer, genetics, Anaplastic Lymphoma Kinase, randomized controlled trial (topic), Neoplasm Metastasis, pemetrexed, cancer survival, Non-Small-Cell Lung, antineoplastic agent, comparative study, Randomized Controlled Trials as Topic, progression free survival, protein kinase inhibitor, Licensed drugs, Antibodies, Monoclonal, Neoplasms, Second Primary, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Progression-Free Survival, 3. Good health, ErbB Receptors, Second Primary, Docetaxel, Advanced NSCLC, 030220 oncology & carcinogenesis, Nintedanib, Erlotinib, pembrolizumab, Immunotherapy, Nivolumab, medicine.drug, atezolizumab, survival rate, medicine.medical_specialty, ramucirumab, overall survival, EGFR protein, Antibodies, Monoclonal, Humanized, clinical decision making, lcsh:RC254-282, Article, cancer chemotherapy, Antibodies, Ramucirumab, 03 medical and health sciences, Erlotinib Hydrochloride, Targeted therapies, Atezolizumab, Internal medicine, medicine, metastasis, Humans, Check point inhibitors, human, second cancer, outcome assessment, protein expression, Protein Kinase Inhibitors, nivolumab, cancer immunotherapy, non small cell lung cancer, treatment duration, business.industry, cancer staging, Carcinoma, immunohistology, drug targeting, clinical assessment, 030104 developmental biology, chemistry, monoclonal antibody, Quality of Life, pathology, business, epidermal growth factor receptor, Immunotherapies

  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10